ClinConnect ClinConnect Logo
Search / Trial NCT00001344

Dextromethorphan Versus Placebo for Neuropathic Pain

Launched by NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH (NIDCR) · Dec 9, 2002

Trial Information

Current as of March 27, 2025

Completed

Keywords

Diabetes Mellitus Diabetic Neuropathy Memantine Nmda Receptor Antagonists Neuropathic Pain Neuropathy Post Herpetic Neuralgia Shingles

ClinConnect Summary

In our current clinical trial, we are comparing the effects of two NMDA receptor antagonists to placebo in patients with painful distal symmetrical diabetic neuropathy or post-herpetic neuralgia. The treatments in this three-period crossover study are dextromethorphan, up to 920 mg/day (about 8 times the antitussive dose), memantine, 30-50 mg/day, and placebo. Memantine is an NMDA antagonist used in Europe to treat Parkinson's disease and Alzheimer's disease. The underlying hypothesis, based on studies of painful neuropathies in animal models, is that neuropathic pain is caused largely by s...

Gender

ALL

Eligibility criteria

  • Patients must be over 18 years of age.
  • Patients must have a definite diagnosis of diabetic neuropathy or post herpetic neuralgia or a diagnosis of neuropathic pain of various etiologies other than diabetic neuropathy or post herpetic neuralgia.
  • Duration of symptoms must be at least 3 months.
  • Severity of pain must be at least mild, if constant; or at least moderate, if intermittent and at least 2 hours duration a day.
  • Patients using tricyclics, narcotics, or antiseizure medications, must keep the drug dosages constant throughout the study.
  • No patients with unstable disease process; i.e., angina pectoris, accelerated hypertension, recent stroke or transient cerebral ischemia, uncontrolled seizures.
  • No pregnant or lactating women. Women of child bearing potential must use birth control pills, intrauterine device, or barrier contraceptive devices.
  • No history of significant drug abuse or PCP use. No history of IV drug abuse, prescription drug abuse, or alcoholism.
  • No significant liver or kidney disease.
  • No MAO inhibitors.
  • No cognitive impairment or language difficulty as judged by difficulty completing pain diary, medical history, or telephone conversation.
  • Patients must not have any other chronic pain condition that gives them pain greater than the neuropathy pain.

About National Institute Of Dental And Craniofacial Research (Nidcr)

The National Institute of Dental and Craniofacial Research (NIDCR) is a pivotal component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of dental and craniofacial disorders. Through innovative research and clinical trials, NIDCR aims to enhance oral health and improve the quality of life for individuals affected by these conditions. The institute fosters collaboration among scientists, clinicians, and public health professionals to translate research findings into practical applications, ensuring that the latest advancements benefit patients and communities. With a commitment to excellence in research and education, NIDCR plays a critical role in shaping the future of oral health care.

Locations

Bethesda, Maryland, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials